Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
Rishi Patel(MACOM (United States)), Marianna Fontana(Johnson & Johnson (United States)), Daniel Knight(MACOM (United States)), Aviva Petrie(Eastman Dental Hospital), Dorota Rowczenio(Children's Cancer and Leukaemia Group), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Liza Chacko(The Royal Free Hospital), Gianfranco Sinagra(University of Trieste), Francesco Bandera(IRCCS Policlinico San Donato), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), James Brown(MACOM (United States)), Charlotte Manisty(National Institutes of Health), Janet A. Gilbertson(Children's Cancer and Leukaemia Group), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Ambra Masi(MACOM (United States)), Carol Whelan(Boston University), Kiara N. Patel(University College London), Ashutosh Wechalekar(Boston University), Yousuf Razvi(MACOM (United States)), Aldostefano Porcari(University of Trieste), Tushar Kotecha(Royal Society), Adam Ioannou(MACOM (United States)), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), James Moon(Virginia Mason Medical Center)
Cited by 94
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k